newsfilter
← Latest News
PR Newswire·

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

LONDON, Dec. 23, 2021 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly ver